Scholarlink

Background <p>Hereditary Spastic Paraplegia (HSP) is a rare genetic neurological disorder that causes progressive spasticity and weakness in the lower limbs. This study aims to describe the prevalence and incidence of HSP and examine common mental health outcomes (depression and anxiety) in HSP patients in England and Northern Ireland.</p> Methods <p>This retrospective cohort study used CPRD Aurum primary care data from 1 January 2000 to 31 December 2021. Annual cross-sectional and cohort studies were conducted for yearly prevalence and incidence of HSP. Common mental health outcomes were examined with a 1:4 matched cohort (age+/−1&#xa0;year, sex, general practice). Descriptive analysis and logistic regression assessed the characteristics of the HSP cohort and baseline depression and anxiety. Cox regression assessed the hazard of new diagnosis of depression and anxiety.</p> Results <p>The overall cohort included 31,302,579 patients; the matched cohort included 1455 HSP patients and 5726 control non-HSP patients. Patients who were male (adjusted odds ratio [aOR] 1.45, 95% CI: 1.31–1.61), of White ethnicity (lower odds in all other ethnicity) and from most other geographical areas compared to London had higher odds of a HSP diagnosis, with the highest odds for North East (aOR 3.51, 95% CI: 2.73–4.50) and Northern Ireland (aOR 3.15, 95% CI: 1.62–6.16). HSP prevalence increased from 2.83 per 100,000 population (95% CI: 2.49–3.20) in 2000 to 6.27 per 100,000 population (95% CI: 5.83–6.73) in 2021. HSP incidence remained stable from 0.12 per 100,000 person-years (95% CI: 0.06–0.22) in 2000 to 0.29 per 100,000 person-years (95% CI: 0.20–0.40) in 2021. HSP patients had higher odds of baseline pre-existing depression (aOR: 1.74, 95% CI: 1.47–2.06) and anxiety (aOR: 1.31, 95% CI: 1.08–1.60); and higher hazard for new diagnosis of depression (adjusted hazard ratio [aHR]: 1.57, 95% CI: 1.26–1.96) and anxiety (aHR: 1.41, 95% CI: 1.12–1.76).</p> Conclusion <p>This first descriptive epidemiological study for HSP in England and Northern Ireland, demonstrated the utility of primary care routine health records for studying rare diseases. The higher rates of common mental health conditions in HSP patients illustrated the importance of access to mental health support.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The epidemiology of hereditary spastic paraplegia and associated common mental health outcomes in England and Northern Ireland

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Harini Jeyakumar,
  • Joht Singh Chandan,
  • Krishnarajah Nirantharakumar,
  • Siang Ing Lee

摘要

Background

Hereditary Spastic Paraplegia (HSP) is a rare genetic neurological disorder that causes progressive spasticity and weakness in the lower limbs. This study aims to describe the prevalence and incidence of HSP and examine common mental health outcomes (depression and anxiety) in HSP patients in England and Northern Ireland.

Methods

This retrospective cohort study used CPRD Aurum primary care data from 1 January 2000 to 31 December 2021. Annual cross-sectional and cohort studies were conducted for yearly prevalence and incidence of HSP. Common mental health outcomes were examined with a 1:4 matched cohort (age+/−1 year, sex, general practice). Descriptive analysis and logistic regression assessed the characteristics of the HSP cohort and baseline depression and anxiety. Cox regression assessed the hazard of new diagnosis of depression and anxiety.

Results

The overall cohort included 31,302,579 patients; the matched cohort included 1455 HSP patients and 5726 control non-HSP patients. Patients who were male (adjusted odds ratio [aOR] 1.45, 95% CI: 1.31–1.61), of White ethnicity (lower odds in all other ethnicity) and from most other geographical areas compared to London had higher odds of a HSP diagnosis, with the highest odds for North East (aOR 3.51, 95% CI: 2.73–4.50) and Northern Ireland (aOR 3.15, 95% CI: 1.62–6.16). HSP prevalence increased from 2.83 per 100,000 population (95% CI: 2.49–3.20) in 2000 to 6.27 per 100,000 population (95% CI: 5.83–6.73) in 2021. HSP incidence remained stable from 0.12 per 100,000 person-years (95% CI: 0.06–0.22) in 2000 to 0.29 per 100,000 person-years (95% CI: 0.20–0.40) in 2021. HSP patients had higher odds of baseline pre-existing depression (aOR: 1.74, 95% CI: 1.47–2.06) and anxiety (aOR: 1.31, 95% CI: 1.08–1.60); and higher hazard for new diagnosis of depression (adjusted hazard ratio [aHR]: 1.57, 95% CI: 1.26–1.96) and anxiety (aHR: 1.41, 95% CI: 1.12–1.76).

Conclusion

This first descriptive epidemiological study for HSP in England and Northern Ireland, demonstrated the utility of primary care routine health records for studying rare diseases. The higher rates of common mental health conditions in HSP patients illustrated the importance of access to mental health support.